Akeso’s first bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials, strengthening leadership in ‘IO+ADC’ 2.0 strategy

CAR-T Digest - August 2020

03 July 2025: Akeso’s first bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials, strengthening leadership in ‘IO+ADC’ 2.0 strategy

Akeso has dosed the first patient in the Phase 1 clinical trial of AK146D1, its first bispecific ADC targeting Trop2 and Nectin4
AK146D1 received clinical trial approvals from the U.S. FDA, Australia’s TGA, and China’s NMPA
AK146D1, the first bispecific ADC targeting both Trop2 and Nectin4, has shown strong preclinical anti-tumor activity and a favorable safety profile
The company is advancing its “IO+ADC 2.0” strategy, aiming to redefine cancer care by combining immunotherapy with innovative ADCs